Nice business plan for as long as partners are available and they do not run out of candidates.
Now, will Aventis follow the same path, for cancer indication?
<< Reimbursement of the Company's VEGF Trap development expenses by the sanofi-aventis Group decreased to $7.1 million in the second quarter of 2005 from $20.7 million in the comparable quarter of 2004, and to $14.5 million in the first six months of 2005 from $34.4 million in the same period of 2004, primarily due to lower clinical supply manufacturing costs. The Company manufactured VEGF Trap clinical supplies during the first six months of 2004, but not during the first six months of 2005.>>
As I mentioned early, currently they are not manufacturing VEGF Trap. Who need it? FOLFOX combination trial is in EU, and Aventis will inform them about outcome day before they are ready to: a) continue or b) cancel program? Nice vision, unless, REGN have spies in EU????
Second though,
<<Regeneron is evaluating the IL-1 Trap in a phase 2b study in rheumatoid arthritis (RA) and is conducting a proof-of-concept study in another indication. The RA trial is being conducted in clinical sites around the world. Participants in this trial will be given placebo, or doses of 160 milligrams (mg) or 320 mg per week, for 24 weeks. The Company plans to initiate several additional proof-of-concept studies of the IL-1 Trap in 2005 in various other diseases.>>
Other indication is OA.
So, they started PIIb RA! Because vast majority of the US RA experts thinks that IL-1 is not crucial for RA development and progress, the only place for PIIB is Siberia and Tanzania (anyone, please no offense).
Good busies plan, indeed!
Miljenko |
